18.26
前日終値:
$18.06
開ける:
$18.1
24時間の取引高:
7.94M
Relative Volume:
0.70
時価総額:
$1.78B
収益:
$2.23B
当期純損益:
$-248.39M
株価収益率:
-6.7881
EPS:
-2.69
ネットキャッシュフロー:
$-697.55M
1週間 パフォーマンス:
-9.51%
1か月 パフォーマンス:
+53.06%
6か月 パフォーマンス:
-82.91%
1年 パフォーマンス:
-86.99%
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
名前
Sarepta Therapeutics Inc
セクター
電話
617-274-4000
住所
215 FIRST STREET, CAMBRIDGE, MA
SRPT を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
SRPT
Sarepta Therapeutics Inc
|
18.26 | 2.05B | 2.23B | -248.39M | -697.55M | -2.69 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
387.18 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
587.65 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
451.20 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
708.09 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
308.91 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-07-29 | アップグレード | Barclays | Underweight → Equal Weight |
2025-07-29 | 開始されました | Bernstein | Mkt Perform |
2025-07-29 | 繰り返されました | H.C. Wainwright | Sell |
2025-07-29 | アップグレード | JP Morgan | Underweight → Neutral |
2025-07-29 | アップグレード | Oppenheimer | Perform → Outperform |
2025-07-28 | ダウングレード | Barclays | Equal Weight → Underweight |
2025-07-25 | ダウングレード | JP Morgan | Neutral → Underweight |
2025-07-24 | 開始されました | Citigroup | Sell |
2025-07-23 | ダウングレード | BofA Securities | Neutral → Underperform |
2025-07-22 | ダウングレード | Barclays | Overweight → Equal Weight |
2025-07-21 | ダウングレード | Deutsche Bank | Buy → Hold |
2025-07-21 | ダウングレード | Leerink Partners | Outperform → Market Perform |
2025-07-21 | ダウングレード | Mizuho | Outperform → Neutral |
2025-07-21 | ダウングレード | Needham | Hold → Underperform |
2025-07-21 | ダウングレード | UBS | Buy → Neutral |
2025-07-18 | ダウングレード | Needham | Buy → Hold |
2025-06-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
2025-06-18 | ダウングレード | TD Cowen | Buy → Hold |
2025-06-17 | 開始されました | Wolfe Research | Peer Perform |
2025-06-16 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
2025-06-16 | ダウングレード | BofA Securities | Buy → Neutral |
2025-06-16 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
2025-06-16 | ダウングレード | H.C. Wainwright | Neutral → Sell |
2025-06-16 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2025-06-16 | ダウングレード | Piper Sandler | Overweight → Neutral |
2025-06-06 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
2025-05-08 | ダウングレード | Evercore ISI | Outperform → In-line |
2025-04-11 | 開始されました | Wells Fargo | Overweight |
2025-04-02 | アップグレード | H.C. Wainwright | Sell → Neutral |
2025-03-31 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
2025-02-11 | 開始されました | Deutsche Bank | Hold |
2024-11-27 | 繰り返されました | Needham | Buy |
2024-11-25 | 開始されました | H.C. Wainwright | Sell |
2024-11-07 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
2024-10-21 | 開始されました | Jefferies | Buy |
2024-10-10 | 再開されました | Raymond James | Outperform |
2024-07-29 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
2024-06-26 | ダウングレード | Citigroup | Buy → Neutral |
2024-05-31 | 開始されました | Piper Sandler | Overweight |
2024-05-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
2024-05-14 | アップグレード | Oppenheimer | Perform → Outperform |
2024-01-31 | 開始されました | BMO Capital Markets | Outperform |
2023-12-13 | 再開されました | Citigroup | Buy |
2023-12-12 | 開始されました | Deutsche Bank | Buy |
2023-11-21 | 開始されました | Wedbush | Outperform |
2023-10-31 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
2023-10-31 | ダウングレード | Oppenheimer | Outperform → Perform |
2023-06-23 | ダウングレード | Evercore ISI | Outperform → In-line |
2023-04-26 | 開始されました | SMBC Nikko | Outperform |
2023-04-04 | 開始されました | Citigroup | Buy |
2023-03-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2022-12-22 | 繰り返されました | BTIG Research | Buy |
2022-12-16 | アップグレード | UBS | Neutral → Buy |
2022-04-04 | 再開されました | Cantor Fitzgerald | Overweight |
2022-01-05 | 繰り返されました | Needham | Buy |
2021-12-09 | アップグレード | Oppenheimer | Perform → Outperform |
2021-11-05 | アップグレード | JP Morgan | Neutral → Overweight |
2021-09-15 | アップグレード | Guggenheim | Neutral → Buy |
2021-08-05 | アップグレード | JP Morgan | Underweight → Neutral |
2021-06-15 | 開始されました | BTIG Research | Buy |
2021-04-26 | 再開されました | Credit Suisse | Neutral |
2021-01-12 | ダウングレード | Citigroup | Buy → Neutral |
2021-01-11 | ダウングレード | UBS | Buy → Neutral |
2021-01-08 | ダウングレード | JP Morgan | Overweight → Underweight |
2021-01-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2021-01-08 | ダウングレード | Raymond James | Outperform → Mkt Perform |
2020-11-11 | 開始されました | Berenberg | Hold |
2020-10-28 | 開始されました | UBS | Buy |
2020-08-25 | 開始されました | Raymond James | Outperform |
2020-08-20 | ダウングレード | Credit Suisse | Outperform → Neutral |
2020-03-31 | 開始されました | Mizuho | Buy |
2019-11-01 | 開始されました | Guggenheim | Buy |
2019-08-21 | 繰り返されました | Needham | Buy |
2019-07-09 | 繰り返されました | Morgan Stanley | Overweight |
2019-07-01 | 繰り返されました | RBC Capital Mkts | Outperform |
2019-04-12 | 開始されました | Evercore ISI | Outperform |
2019-03-11 | 繰り返されました | Credit Suisse | Outperform |
2018-10-12 | 開始されました | Bernstein | Outperform |
2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
2018-09-26 | 繰り返されました | RBC Capital Mkts | Outperform |
2018-09-14 | 再開されました | BofA/Merrill | Buy |
2018-09-06 | 開始されました | Credit Suisse | Outperform |
2018-08-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2018-06-21 | 繰り返されました | Robert W. Baird | Outperform |
2018-06-20 | 繰り返されました | Needham | Buy |
2018-06-19 | 繰り返されました | H.C. Wainwright | Buy |
すべてを表示
Sarepta Therapeutics Inc (SRPT) 最新ニュース
Elanco Animal Health to Replace Sarepta Therapeutics in S&P MidCap 400 - MarketScreener
Trading Systems Reacting to (SRPT) Volatility - news.stocktradersdaily.com
Investors in Sarepta Therapeutics, Inc. (SRPT): Protect Your RightsContact Levi & Korsinsky Before August 25, 2025 - Newsfile
SRPT Stock Plunge: Time to Panic? - StocksToTrade
SAREPTA FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
Securities Lawsuit Alert: Sarepta Therapeutics, Inc. (SRPT)Contact Levi & Korsinsky Before August 25, 2025 - Barchart.com
Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) Seeking Recovery for InvestorsContact The Gross Law Firm - PR Newswire
Sarepta Therapeutics (SRPT): Assessing Valuation After Lawsuits and FDA Scrutiny Over ELEVIDYS Safety Concerns - Yahoo Finance
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - WV News
INVESTOR DEADLINE MONDAY: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitSRPT - PR Newswire
Sarepta Therapeutics: A Strong Opportunity Amidst The Panic (NASDAQ:SRPT) - Seeking Alpha
SRPT FINAL DEADLINE: ROSEN, A LEADING NATIONAL FIRM, - GlobeNewswire
Sarepta Gets Breathing Room With $700 Million Debt Restructuring - Bloomberg
Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027 - Business Wire
Jim Cramer on Sarepta Therapeutics: "If it Goes Up, You Gotta Do Some Selling" - Yahoo Finance
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
2025-08-20 | Lost Money on Sarepta Therapeutics, Inc. (SRPT)? Contact Levi & Korsinsky Before August 25, 2025 to Join Class Action | NDAQ:SRPT | Press Release - Stockhouse
SRPT Investors Have the Opportunity to Lead the Sarepta - GlobeNewswire
SRPT Investors Have the Opportunity to Lead the Sarepta Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - Morningstar
BofA Securities Adjusts Price Target on Sarepta Therapeutics to $17 From $10, Maintains Underperform Rating - MarketScreener
What MACD and RSI say about Sarepta Therapeutics Inc.Profit Target & Risk Controlled Swing Alerts - Newser
Will Sarepta Therapeutics Inc. bounce back from current supportWeekly Risk Summary & Fast Exit/Entry Strategy Plans - Newser
Precision Trading with Sarepta Therapeutics Inc. (SRPT) Risk Zones - news.stocktradersdaily.com
Sarepta Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
Sarepta Therapeutics, Inc. (SRPT) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of August 25, 2025 Deadline - Barchart.com
Sarepta Therapeutics, Inc. Class Action: Levi & Korsinsky - GlobeNewswire
Earnings visualization tools for Sarepta Therapeutics Inc.2025 EndofYear Setup & Intraday High Probability Alerts - Newser
Burned by Sarepta Therapeutics, Inc.? Contact Levi & Korsinsky to SueWallSt and Fight Back - ACCESS Newswire
SRPT’s Stock Dilemma: Sarepta Therapeutics Inc’s Market Performance and Outlook - investchronicle.com
Shareholders that lost money on Sarepta Therapeutics, Inc.(SRPT) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - Morningstar
SRPT SECURITIES: Sarepta Therapeutics, Inc. Shareholders that Lost Money may have been Affected by Fraud -- Contact BFA Law before the Class Action Deadline (NASDAQ:SRPT) - GlobeNewswire
Sarepta Therapeutics, Inc. $SRPT Shares Sold by Maryland State Retirement & Pension System - Defense World
PNC Financial Services Group Inc. Has $149,000 Stock Holdings in Sarepta Therapeutics, Inc. $SRPT - Defense World
Sarepta Therapeutics Inc. stock daily chart insightsJuly 2025 Trade Ideas & Safe Swing Trade Setup Alerts - Newser
Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) Over Securities ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
Robbins LLP Reminds Sarepta Therapeutics, Inc. Stockholders - GlobeNewswire
Contact The Gross Law Firm by August 25, 2025 Deadline to - GlobeNewswire
Arrowhead (ARWR) Climbs 24.9% on $100-Million Licensing Revenue - Yahoo Finance
Sarepta Therapeutics (SRPT) August 25, 2025 Lead Plaintiff - GlobeNewswire
Investors In Sarepta Therapeutics, Inc. (SRPT): Protect Your RightsContact Levi & Korsinsky Before August 25, 2025 - Barchart.com
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc.(SRPT) Shareholders - Morningstar
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
SRPT LOSSES: Sarepta Therapeutics, Inc. Investors with Losses are Encouraged to Contact BFA Law before Expiration of August 25 Class Action Deadline - Newsfile
How the Moms and Dads of Patients Won Sarepta’s Drug a Reprieve - Bloomberg.com
SRPT INVESTOR NOTICE: Robbins Geller Ruman & Dowd LLP - GlobeNewswire
Will Sarepta Therapeutics Inc. outperform the marketPortfolio Update Summary & Pattern Based Trade Signal System - Newser
Sarepta Therapeutics, Inc. $SRPT Shares Sold by LPL Financial LLC - Defense World
SRPT LOSS ALERT: Sarepta Therapeutics, Inc. Investors with - GlobeNewswire
SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities LawsuitContact the DJS Law Group Before the Final DeadlineSRPT - MarketScreener
How Sarepta Therapeutics Inc. (SRPT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Sarepta Therapeutics Inc (SRPT) 財務データ
収益
当期純利益
現金流量
EPS
Sarepta Therapeutics Inc (SRPT) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Barry Richard | Director |
May 16 '25 |
Option Exercise |
32.63 |
12,350 |
402,981 |
2,966,667 |
Barry Richard | Director |
May 13 '25 |
Option Exercise |
19.23 |
20,246 |
389,359 |
2,954,317 |
Nicaise Claude | Director |
Mar 12 '25 |
Option Exercise |
25.18 |
9,746 |
245,404 |
30,303 |
Nicaise Claude | Director |
Mar 12 '25 |
Sale |
99.64 |
2,491 |
248,203 |
27,812 |
大文字化:
|
ボリューム (24 時間):